Eli Lilly (LLY) stock extended gains on Tuesday and Wednesday after the pharmaceutical behemoth said it’s buying three private vaccine makers for nearly $4 billion.
The upward momentum drove LLY’s relative strength index (RSI) into the late 60s, indicating the stock is now approaching overbought territory.